A novel small molecule phagocytosis inhibitor, KB‐208, ameliorates ITP in mouse models with similar efficacy as IVIG
Open Access
- 7 November 2024
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 64 (12) , 2233-2240
Abstract
Background: The characteristic feature of immune cytopenias involves the process of extravascular phagocytosis, wherein macrophages in the spleen and/or liver engage in the destruction of blood cells that have been opsonized by auto‐ or alloantibodies. Therefore, new treatments that prevent phagocytosis will be advantageous, especially for short‐term usage along with alternative options.Study Design and Methods: KB‐208, a small molecule drug, previously shown to be efficacious for the in vitro inhibition of phagocytosis was synthesized. A passive antibody mouse model of immune thrombocytopenia (ITP) was used. Three different mouse strains (BALB/c, C57BL/6, CD1) were used to determine the efficacy of KB‐208 compared with IVIG to ameliorate the ITP. Toxicity was investigated after 60‐day chronic administration of KB‐208 by a biochemistry panel, gross necroscopy and histopathology.Results: KB‐208 showed similar efficacy to ameliorate the thrombocytopenia compared with IVIG in all three mouse strains. This small molecule drug was effective at 1 mg/kg in ameliorating ITP, in comparison with IVIG at 1000–2500 mg/kg. KB‐208 did not affect other blood parameters or elevate serum biochemistry markers of toxicity nor were any abnormal histopathological findings found.Conclusion: KB‐208 is similar to IVIG for the amelioration of ITP in multiple mouse strains. Chronic administration of KB‐208 for 60 days did not demonstrate in vivo toxicity. These findings indicate that KB‐208 is efficacious, without significant in vivo toxicities in mice, and is a potential small molecule candidate for further evaluation to be used in the treatment of ITP and possibly all immune cytopenias where phagocytosis is responsible for the pathophysiology.Keywords
Funding Information
- Canadian Blood Services (IRGP2024‐Branch)
This publication has 15 references indexed in Scilit:
- Novel treatments for immune thrombocytopenia: targeting platelet autoantibodiesExpert Review of Hematology, 2024
- Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double‐blind, placebo‐controlled, global study (FORWARD)American Journal of Hematology, 2023
- In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinibPharmacology Research & Perspectives, 2015
- Romiplostim promotes platelet recovery in a mouse model of multicycle chemotherapy-induced thrombocytopeniaExperimental Hematology, 2015
- Sialylation‐independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulinTransfusion, 2012
- Improved mouse models for the study of treatment modalities for immune‐mediated platelet destructionTransfusion, 2010
- The SYK tyrosine kinase: a crucial player in diverse biological functionsNature Reviews Immunology, 2010
- Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of SykBlood, 2009
- Drug-Induced Immune Hemolytic Anemia2004
- The Immune CytopeniasPostgraduate Medicine, 1973